Skip to main content

An Overview of Safety Data From the RINVOQ™ (upadacitinib) Phase 3 Program

Dec 02, 2019 3:58 pm

Sponsored by AbbVie

Dr. Stanley Cohen presents safety data from both the short-term controlled and long-term portions of the SELECT Phase 3 Program with RINVOQ™.

Content developed by AbbVie Inc. This content is intended for US/PR Healthcare Professionals. The US Medical Affairs department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written and oral content within this presentation © [2019] AbbVie Inc. All rights reserved. The speaker has received compensation from the US Medical Affairs department of AbbVie Inc. to prepare and present this information and is speaking on behalf of AbbVie.